Benzinga | Mar 22, 2021 07:54AM EDT

InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company's Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders

InspireMD, Inc. (NYSE:NSPR), developer of the CGuard(tm) Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO, Marvin Slosman regarding the Company's Special Meeting of Stockholders.

To our valued Stockholders:

We have adjourned our Stockholder Meeting until April 14, 2021 in order to provide additional time for stockholders with a record date of February 8, 2021 to vote for the outstanding proposals.

The primary purpose of the vote is to advance our strategy to move to Nasdaq as a preferred platform for our company as provided in the link below to our proxy statement.

https://www.sec.gov/Archives/edgar/data/1433607/000149315221003331/formdef14a.htm

The Company is seeking authorization to affect a reverse stock split to help meet the criteria required to obtain an initial listing on Nasdaq.

I, along with other senior management of the Company, own shares of NSPR just as you do and have voted in favor of the reverse stock split proposal. As outlined in the proxy statement, we believe that listing our common stock on Nasdaq will make NSPR more attractive to a broader range of investors.

If you are a stockholder of record as of February 8, 2021, please dial the number below to vote.

WE URGE YOU TO VOTE NOW BY CALLING KINGSDALE ADVISORS AT 1-866-581-1479 or collect at 1-416-867-2272 AND ONE OF THEIR AGENTS WOULD BE HAPPY TO HELP YOU VOTE OVER THE PHONE.

Thank you for your support,

Marvin Slosman

CEO

InspireMD